Abstract: An active balancing control apparatus and method with an active balancing algorithm to charge and discharge a plurality of batteries connected in series. The active balancing control apparatus may be designed to simultaneously charge and discharge a plurality of batteries, connected in series and having different charge/discharge characteristics, using an active balancing circuit. The apparatus may perform switching to achieve balancing of each of the batteries so that all the batteries may be charged at a maximum voltage.

Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Abstract: An algorithm and a direct current (DC) microgrid charge/discharge system with the algorithm are provided that noticeably increases charge/discharge voltage during charging and discharging by connecting a plurality of secondary batteries in series, compared to a single battery, that increases power conversion efficiency of a DC-to-DC (DC/DC) converter for charge/discharge power control by setting an appropriate voltage of a DC microgrid to be about twice a maximum voltage of a battery group, that enables charging and discharging to be stably performed regardless of a change in the battery group by adding a linear constant current source, that increases power conversion efficiency of the DC microgrid charge/discharge system by configuring a DC energy storage system (ESS) used for both charging and discharging with a combination of a typical electrolytic condenser and a super condenser or a group of the secondary batteries, and that simplifies the DC microgrid charge/discharge system.

Abstract: A monitoring apparatus and method of a battery contact point that autonomously measures contact resistances of a contact terminal for directly connecting a battery for charging/discharging and a circuit in a charge/discharge apparatus for charging/discharging a single secondary battery or a plurality of secondary batteries in series.

Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Abstract: A monitoring apparatus and method of a battery contact point that autonomously measures contact resistances of a contact terminal for directly connecting a battery for charging/discharging and a circuit in a charge/discharge apparatus for charging/discharging a single secondary battery or a plurality of secondary batteries in series.

Abstract: An active balancing control apparatus and method with an active balancing algorithm to charge and discharge a plurality of batteries connected in series. The active balancing control apparatus may be designed to simultaneously charge and discharge a plurality of batteries, connected in series and having different charge/discharge characteristics, using an active balancing circuit. The apparatus may perform switching to achieve balancing of each of the batteries so that all the batteries may be charged at a maximum voltage.

Abstract: An algorithm and a direct current (DC) microgrid charge/discharge system with the algorithm are provided that noticeably increases charge/discharge voltage during charging and discharging by connecting a plurality of secondary batteries in series, compared to a single battery, that increases power conversion efficiency of a DC-to-DC (DC/DC) converter for charge/discharge power control by setting an appropriate voltage of a DC microgrid to be about twice a maximum voltage of a battery group, that enables charging and discharging to be stably performed regardless of a change in the battery group by adding a linear constant current source, that increases power conversion efficiency of the DC microgrid charge/discharge system by configuring a DC energy storage system (ESS) used for both charging and discharging with a combination of a typical electrolytic condenser and a super condenser or a group of the secondary batteries, and that simplifies the DC microgrid charge/discharge system.

Abstract: Disclosed herein are 5,?-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,?-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.

Abstract: Disclosed herein are 5,?-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,?-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.

Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angiogenesis, and also a method for preparing the same.

Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angiogenesis, and also a method for preparing the same.

Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angeogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angeogeneois, and also a method for preparing the same.

Abstract: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angeogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease, psoriasis, etc., and diabetic retinopathy related to angeogeneois, and also a method for preparing the same.

Abstract: Compounds useful as angiogenesis inhibiting agents and processes for their preparation are disclosed. In one embodiment, the compounds of the invention are represented by Formula 1: ##STR1## Also disclosed is a pharmaceutical composition for inhibiting angiogenesis in a mammal, said composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.